LABS.TO - MediPharm Labs Corp.

Toronto - Toronto Delayed Price. Currency in CAD
1.1700
-0.0500 (-4.10%)
As of 10:04AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.2200
Open1.2200
Bid1.1700 x N/A
Ask1.1800 x N/A
Day's Range1.1600 - 1.2300
52 Week Range1.0700 - 7.2800
Volume67,510
Avg. Volume781,432
Market Cap157.626M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateAug. 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.98
  • Canadians: 3 Stocks Under $5 to Watch in July
    The Motley Fool

    Canadians: 3 Stocks Under $5 to Watch in July

    Some Canadians may want to consider micro-cap stocks like MediPharm Labs Corp. (TSX:LABS) as a buy-low opportunity this month.The post Canadians: 3 Stocks Under $5 to Watch in July appeared first on The Motley Fool Canada.

  • CNW Group

    Cannabis & CBD Biopharma Investor Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , July 10, 2020 /CNW/ - Virtual Investor Conferences, the ...

  • CNW Group

    Live Investor Conference & Webinar: Cannabis & CBD Biopharma Industry Companies Present July 9th

    Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , July 7, 2020 /CNW/ - Virtual Investor Conferences today announced the agenda for the upcoming ...

  • GlobeNewswire

    MediPharm Labs Sets Date to Release Second Quarter 2020 Financial Results

    BARRIE, Ontario, July 02, 2020 -- MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized,.

  • GlobeNewswire

    MediPharm Labs Expands Innovative CBD Product Portfolio By Introducing CBD25:5 Release Formula

    TORONTO, June 25, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • GlobeNewswire

    REPEAT - MediPharm Labs Appoints Former Nestlé Canada President and CEO, Shelley Martin, to Board of Directors

    Ms. Martin served in a variety of senior executive roles at Nestlé Canada Inc. from 1990 until she retired after five years as President and Chief Executive Officer in 2018. During her time leading Nestlé Canada, she drove a substantial increase in revenue, market share and profitability and transformed core business units and brands by introducing new formulas, packaging, pricing, global sources of supply and Lean (Six Sigma) tools. In 2018, Nestlé Canada’s annual sales were approximately $2.6 billion.

  • GlobeNewswire

    MediPharm Labs Appoints Former Nestlé Canada President and CEO, Shelley Martin, to Board of Directors

    Ms. Martin served in a variety of senior executive roles at Nestlé Canada Inc. from 1990 until she retired after five years as President and Chief Executive Officer in 2018. During her time leading Nestlé Canada, she drove a substantial increase in revenue, market share and profitability and transformed core business units and brands by introducing new formulas, packaging, pricing, global sources of supply and Lean (Six Sigma) tools. In 2018, Nestlé Canada’s annual sales were approximately $2.6 billion.

  • GlobeNewswire

    Proactive Virtual Event Showcases Four Rising Stars of the Life Sciences Industry

    NEW YORK, June 22, 2020 -- Proactive, the digital financial news organization, will be showcasing four rising stars of the life sciences industry with its first North American.

  • Baystreet

    Stocks in play: MediPharm Labs Corp.

    Announced that its subsidiary, MediPharm Labs Australia Pty. Ltd. has entered into an agreement to supply ...

  • GlobeNewswire

    MediPharm Labs Australia Enters Into New Supply Agreement With VIVO Cannabis and Prepares to Commence Sales

    Large shipment of 35,000 units of formulated finished products and bulk extract completed to MPL Australia to support commencement of sales revenue TORONTO, June 19, 2020 --.

  • VIVO Cannabis™ Enters Into New Supply Agreement With Medipharm Labs Australia
    CNW Group

    VIVO Cannabis™ Enters Into New Supply Agreement With Medipharm Labs Australia

    NAPANEE, ON , June 19, 2020 /CNW/ - VIVO Cannabis Inc. (VIVO.TO), (VVCIF) ("VIVO" or the "Company") today announced that its subsidiary, Beacon Medical Australia Pty. Ltd. ("Beacon Medical Australia"), entered into an agreement with MediPharm Labs Australia Pty. Ltd. ("MediPharm Labs Australia"), a subsidiary of MediPharm Labs Corp. (LABS.TO) ("MediPharm Labs"), whereby MediPharm Labs Australia will supply pharmaceutical-quality (GMP certified), formulated cannabis oil products to Beacon Medical Australia to sell into the Australian market. "VIVO's international efforts remain focused on the emerging Australian and German markets and we continue to seek out partnerships with organizations that have proven track records," said Barry Fishman , CEO of VIVO.

  • GlobeNewswire

    MediPharm Labs Announces Participation at Upcoming Conferences

    BARRIE, Ontario, June 19, 2020 -- MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized,.

  • GlobeNewswire

    MediPharm Labs Reports First Quarter 2020 Results, Clears Path for International Growth

    The Company also provided an update on the build out of its global Good Manufacturing Practices (“GMP”) certified production platforms and new international medicinal, wellness and adult use-recreational revenue streams. “MediPharm Labs has proudly evolved from our beginning stages to today, capitalizing on a multi-jurisdictional GMP-certified manufacturing footprint to further develop a diversified international customer portfolio with multiple product streams suitable for lawful medicinal, wellness and adult-use recreational markets around the world,” said Pat McCutcheon, CEO, MediPharm Labs. “Our focus on innovation, a pharmaceutical approach, capital investments and the very high standards achieved through the GMP certification of our Canadian and Australian facilities will allow us to further evolve our business as we pursue medicinal and wellness markets, as well as international opportunities, so that we are not reliant on the challenged Canadian recreational market.”

  • GlobeNewswire

    MediPharm Labs Sets Date to Release First Quarter 2020 Financial Results and Provides Corporate Update

    BARRIE, Ontario, June 11, 2020 -- MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized,.

  • GlobeNewswire

    MediPharm Labs Closes $37.8 Million Private Placement

    TORONTO, June 08, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • GlobeNewswire

    MediPharm Labs Accelerates Growth of Pharma-Quality Product Portfolio With Launch of its New CBD50 Plus Formula

    TORONTO, June 04, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven.

  • Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement
    CNW Group

    Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement

    TORONTO, June 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs ("MediPharm") (TSX:LABS.TO - News)(OTCQX:MEDIF - News)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products. Orders under the agreement will be composed of a mix of Canntab's proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths. MediPharm will purchase and distribute cannabis products on a non-exclusive basis across Canada, through licensed provincial dispensaries.

  • A Medical Cannabis Stock for Millennial Investors
    The Motley Fool

    A Medical Cannabis Stock for Millennial Investors

    The cannabis sector is still very young with enormous risks. There are great ideas in the space, especially when it comes to medical uses. Medipharm Labs Corp. (TSX:LABS) has an excellent business model that should grow over time. It is perfect for millennial investors with long time horizons.The post A Medical Cannabis Stock for Millennial Investors appeared first on The Motley Fool Canada.

  • GlobeNewswire

    MediPharm Labs and Argentia Gold to Bring Premium Cannabis-Infused Products to Atlantic Canada

    Under the agreement, which has an initial 2-year term, MediPharm Labs will provide Argentia Gold-branded formulated tincture bottles of CBD cannabis resin and Argentia Gold will provide distribution, sales, and service to leading retailers in Newfoundland and Labrador, Prince Edward Island, Nova Scotia and New Brunswick. “We are committed to delivering the highest quality products to our customers throughout Atlantic Canada and doing so in partnership with MediPharm Labs is a virtual guarantee of success,” said Dave Thomson, President of Argentia Gold.

  • GlobeNewswire

    REPEAT – MediPharm Labs and Ace Valley Deliver Innovative Vapes - Now Available in Several Markets Across Canada

    The launch of the Ace Valley Vapes is the culmination of the Company’s previously announced white label agreement through its subsidiary, MediPharm Labs Inc., with AV Cannabis Inc. (d/b/a Ace Valley). Through this collaboration, Ace Valley leveraged its leading brand traction and product strategy expertise to design, brand and market new and innovative vaporizer products, while MediPharm Labs provided raw material from its supply chain, high-quality cannabis distillate, formulation and filling expertise from its GMP-certified facility, as well as distribution services across Canada to cannabis distributors and retailers.

  • GlobeNewswire

    MediPharm Labs and Ace Valley Deliver Innovative Vapes - Now Available in Several Markets Across Canada

    The launch of the Ace Valley Vapes is the culmination of the Company’s previously announced white label agreement through its subsidiary, MediPharm Labs Inc., with AV Cannabis Inc. (d/b/a Ace Valley). Through this collaboration, Ace Valley leveraged its leading brand traction and product strategy expertise to design, brand and market new and innovative vaporizer products, while MediPharm Labs provided raw material from its supply chain, high-quality cannabis distillate, formulation and filling expertise from its GMP-certified facility, as well as distribution services across Canada to cannabis distributors and retailers.

  • GlobeNewswire

    MediPharm Labs Australia Signs First European White-Label Cannabis Supply Agreement With UK-Based Cannaray’s Therismos

    Under the three-year agreement, MediPharm Labs Australia will supply a range of cannabis oil products that meet the high-quality standards set by the German Institute for Drugs and Medical Devices that requires all medicinal cannabis products be manufactured under Good Manufacturing Practices (“GMP”). Cannaray, a leading UK-based medical cannabis and CBD lifestyle product company, recently acquired Therismos, a specialist pharmaceutical company with licences to import, handle, and distribute controlled drugs in various European countries.

  • GlobeNewswire

    MediPharm Labs Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with Biopharmaceutical Leader Avicanna Inc.

    MediPharm Labs Corp., (LABS.TO) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that it has signed a multi-faceted strategic manufacturing agreement with Avicanna Inc. (TSX: AVCN) (AVCNF) (0NN.F) (“Avicanna”) involving licensed production, domestic and international distribution and intellectual property licensing. Avicanna is a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products. Under the agreement, which has an initial three-year term, MediPharm Labs will use the specialized contract manufacturing capabilities resident at its state-of-the-art Canadian production facility to produce Avicanna’s advanced Rho Phyto™ medical cannabis products and Pura Earth™ topicals under license for commercial sales through Medical Cannabis by Shoppers™.

  • Avicanna Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with World-Class Canadian Manufacturer MediPharm Labs
    CNW Group

    Avicanna Signs Wide-Ranging Strategic Manufacturing and IP Licensing Agreement with World-Class Canadian Manufacturer MediPharm Labs

    MediPharm Labs is a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products. Under the agreement, which has an initial three-year term, MediPharm Labs will use the specialized contract manufacturing capabilities resident at its state-of-the-art Canadian production facility to produce Avicanna's advanced Rho Phyto™ medical cannabis products and Pura Earth™ topicals under license for commercial sales through Medical Cannabis by Shoppers™.

  • GlobeNewswire

    MediPharm Labs to File First Quarter Financial Statements and MD&A in June 2020, Provides Q1 Update

    In accordance with the blanket exemption, the Company is not permitted to file any preliminary or final prospectus while it is relying on this filing deadline relief. Pending the filing of the First Quarter Financial Information, the Company is providing an update on the impact of COVID-19 and material business developments since the date of the Company’s latest financial reports filed on March 30, 2020, certain of which have already been disclosed in prior press releases.